Skip to main content
CCL Products (India) Ltd. logo

CCL Products (India) Ltd. — Investor Relations & Filings

Ticker · CCL ISIN · INE421D01022 LEI · 3358004YMWO3ILPLLM24 BSE.NS Manufacturing
Open in API
Filings indexed 1,203 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country IN India
Listing BSE.NS CCL

About CCL Products (India) Ltd.

https://www.cclproducts.com

CCL Products (India) Ltd. is a global manufacturer and exporter specializing in instant coffee production. The company provides a comprehensive range of products, including spray-dried coffee powder, freeze-dried coffee, coffee granules, and roasted coffee beans. It operates advanced processing facilities to supply customized coffee solutions to private labels, major retailers, and institutional clients across more than 90 international markets. The product portfolio encompasses pure coffee and chicory-blended varieties, designed to meet specific quality standards. By utilizing large-scale production capacities and sophisticated processing technologies, the organization maintains a significant role in the global supply chain, focusing on product consistency and technical excellence for diverse market requirements.

Recent filings

Filing Released Lang Actions
The Board of Directors in their meeting held on 05.02.2025 has approved the shifting of Corporate office of the Company from 7-1-24/2/D, Greendale, Ameerpet, Hyderabad, Telangana - 500016 ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board Meeting. It announces the approval of un-audited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2024. It also mentions a corporate office relocation. The document is short (1864 characters) and primarily serves as an announcement of the board meeting decisions and financial results approval, not the full financial report itself. There is no detailed financial data or analysis included, only a summary of decisions. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement of financial results approval and other corporate actions, not the full Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-02-05 English
Updates
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board Meeting. It announces the approval of un-audited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2024. It also mentions a corporate office relocation. The document is short (1864 characters) and primarily serves as an announcement of the board meeting decisions, including financial results approval, rather than containing the full financial report or detailed financial data. Therefore, it is not an Interim/Quarterly Report (IR) itself but an announcement of the board meeting outcome and financial results approval. This fits best under Board/Management Information (MANG) as it reports board decisions and changes. Confidence is high due to clear references to board meeting outcomes and financial results approval without detailed financial statements.
2025-02-05 English
Please find attached the Integrated filing (Financial) for the third quarter and nine months ended 31st December, 2024
Regulatory Filings
2025-02-05 English
Please find attached the unaudited financial results of the company (Standalone and Consolidated) for the third quarter and nine months ended 31st December, 2024.
Regulatory Filings
2025-02-05 English
Integrated Filing- Financial
Regulatory Filings
2025-02-05 English
We wish to inform you that the Board of Directors of the Company, at their just concluded meeting have decided on the following: 1. Approved the Un-audited Standalone Financial Results ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board Meeting. It specifically mentions the approval of un-audited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2024. It also includes a corporate office relocation announcement. The document is short (1864 characters) and primarily serves as an announcement of the board meeting decisions, including financial results approval, rather than containing the full financial statements or detailed analysis. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement informing the exchanges and public about board decisions and financial results approval, not the full interim report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-02-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.